Finanzen von Tenaya Therapeutics Inc (TNYA)TNYATenaya Therapeutics Inc

Evaluating the bottom line, Tenaya Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1153.33%, while the net margin is -1115.97%. These profitability ratios, combined with a Return on Equity (ROE) of -148.16%, provide a clear picture of how effectively TNYA converts its operational activities into shareholder value.

In the context of the broader market, TNYA competes directly with industry leaders such as CRBP and ATRA. With a market capitalization of $72.03M, it holds a significant position in the sector. When comparing efficiency, TNYA's gross margin of N/A stands against CRBP's N/A and ATRA's 69.68%. Such benchmarking helps identify whether Tenaya Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Tenaya Therapeutics has reported zero revenue in the last four quarters, with significant net income losses. In Q2 2026, the company reported a net loss of $43,393,000. The gross margin has recently improved to 100%, but this is not indicative of a sustainable business model.